Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways.
Serine proteases such as thrombin, trypsin and mast cell tryptase can act on different cell types through protease-activated receptors (PARs). These receptors have been shown to be implicated in several phenomena such as inflammation, platelet activation, immune response and atherosclerosis. Several studies recently reported PARs expression on neurons and some of them demonstrated that these receptors could interfere with nociception. The contribution of PAR(1) to inflammatory pain and the mechanism involved in this phenomenon were investigated. Intraplantar injection of PAR(1) agonist increased withdrawal latency and reduced response frequency to von Frey filaments, thus inhibiting nociceptive response to both mechanical and thermal stimuli in mice. PAR(1) agonist also reduced carrageenan-induced inflammatory hyperalgesia. The anti-nociceptive effects of PAR(1) agonist were mediated by endogenous opioids, as this effect was inhibited by local injection of naloxone methiodide, and because intraplantar injection of PAR(1) agonist increased mRNA expression of the endogenous opioid precursor proenkephalin. However, PAR(1) agonist was not able to inhibit calcium signals in isolated sensory neurons exposed to pro-nociceptive agents. Finally, despite similar inflammatory parameters, PAR(1)-deficient mice showed a strong potentiation of inflammatory hyperalgesia induced by the intraplantar injection of either formalin or carrageenan, or in the chronic model of collagen-induced arthritis, compared to wild-type mice. This study highlights a previously unknown endogenous mechanism of analgesia, showing a central role for the thrombin receptor PAR(1) in the regulation of inflammatory pain and as an activator of opioid pathways.
Martin
Laurence
L
INSERM, U563, Centre de Physiopathologie de Toulouse Purpan, F-31000 Toulouse, France.
Augé
Céline
C
Boué
Jérôme
J
Buresi
Michelle C
MC
Chapman
Kevin
K
Asfaha
Samuel
S
Andrade-Gordon
Patricia
P
Steinhoff
Martin
M
Cenac
Nicolas
N
Dietrich
Gilles
G
Vergnolle
Nathalie
N
D000818:Animals; D002118:Calcium / Q000378:metabolism; D005528:Foot; D006930:Hyperalgesia / Q000139:chemically induced / Q000473:pathology; D007150:Immunohistochemistry; D007249:Inflammation / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology*; D007267:Injections; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009619:Nociceptors / Q000187:drug effects; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology; D018847:Opioid Peptides / Q000502:physiology*; D010146:Pain / Q000139:chemically induced / Q000209:etiology / Q000503:physiopathology*; D010147:Pain Measurement / Q000187:drug effects; D044463:Receptor, PAR-1 / Q000819:agonists / Q000502:physiology; D011957:Receptors, Opioid / Q000187:drug effects; D018179:Receptors, Thrombin / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D011984:Sensory Receptor Cells / Q000187:drug effects; D015398:Signal Transduction / Q000502:physiology
D009842:Oligopeptides; D018847:Opioid Peptides; C462999:PAR-1-activating peptide; D044463:Receptor, PAR-1; D011957:Receptors, Opioid; D018179:Receptors, Thrombin; D002118:Calcium